Healthcare / Medical Instruments & SuppliesStockholm
$276.00
+3.00 (+1.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $24.4M · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
62/100
B
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
39.9x
↑EV/EBITDA
21.4x
↑ROE
7.9%
↑Gross Margin
50.7%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+32.1%
FCF CAGR
-13.5%
FCF margin
2.7%
FCF / Net income
0.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $567.6M · net income $55.7M · FCF $15.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $567.6M | $567.6M | $570.0M | $294.9M | $246.3M |
| Net Income | $55.7M | $55.7M | $58.2M | $26.6M | $27.3M |
| EBITDA | $115.9M | $115.9M | $119.0M | $56.0M | $44.8M |
| EPS | 6.20 | 6.20 | 6.48 | 5.31 | 5.45 |
| Gross Margin | 50.7% | 50.7% | 51.9% | 44.8% | 45.3% |
| Operating Margin | 14.7% | 14.7% | 20.2% | 16.5% | 13.2% |
| Net Margin | 9.8% | 9.8% | 10.2% | 9.0% | 11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.09 | 0.10 | 0.37 |
| Current Ratio | 3.52 | 3.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.5M | $15.5M | $58.6M | $24.4M | $23.9M |
| Returns | |||||
| ROE | 7.9% | 7.9% | 8.3% | 4.2% | 14.4% |
| Valuation | |||||
| P/E | 39.94 | 39.94 | 31.64 | 27.40 | 21.01 |
| EV/EBITDA | 21.43 | 21.43 | 14.68 | 9.84 | 13.58 |
| P/B | 3.50 | 3.50 | 2.63 | 1.15 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | -0.4% | -0.4% | 93.3% | 19.7% | — |
| EPS Growth | -4.3% | -4.3% | 22.0% | -2.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
58.1%
EPS terminal req.
$24.49
Spread vs growth
-62.4%
5Y implied EPS CAGR
36.7%
EPS terminal req.
$29.63
Spread vs growth
-41.1%
10Y implied EPS CAGR
22.6%
EPS terminal req.
$47.72
Spread vs growth
-27.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.8%
Start / end P/E
33.3x → 44.5x
EPS bridge
6.48 → 6.20
Residual
-1.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.